title: Biomarker Development for Chronic Obstructive Pulmonary Disease. From Discovery to Clinical Implementation.
abstract: Chronic obstructive pulmonary disease (COPD) is one of the major causes of morbidity and mortality in the world. Regrettably, there are no biomarkers to objectively diagnose COPD exacerbations, which are the major drivers of hospitalization and deaths from COPD. Moreover, there are no biomarkers to guide therapeutic choices or to risk stratify patients for imminent exacerbations and no objective biomarkers of disease activity or disease progression. Although there has been a tremendous investment in COPD biomarker discovery over the past 2 decades, clinical translation and implementation have not matched these efforts. In this article, we outline the challenges of biomarker development in COPD and provide an overview of a developmental pipeline that may be able to surmount these challenges and bring novel biomarker solutions to accelerate therapeutic discoveries and to improve the care and outcomes of the millions of individuals worldwide with COPD.
authors.affiliation: 1 Centre for Heart Lung Innovation, James Hogg Research Centre, St. Paul's Hospital, Vancouver, British Columbia, Canada.|2 Institute for Heart and Lung Health.|3 Division of Respiratory Medicine, Department of Medicine.
authors.forename: Don D
authors.initials: DD
authors.lastname: Sin
authors.affiliation: 1 Centre for Heart Lung Innovation, James Hogg Research Centre, St. Paul's Hospital, Vancouver, British Columbia, Canada.|2 Institute for Heart and Lung Health.|4 PROOF Centre of Excellence, Vancouver, British Columbia, Canada.
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Hollander
authors.affiliation: 5 Department of Pathology and Laboratory Medicine, and.
authors.forename: Mari L
authors.initials: ML
authors.lastname: DeMarco
authors.affiliation: 1 Centre for Heart Lung Innovation, James Hogg Research Centre, St. Paul's Hospital, Vancouver, British Columbia, Canada.|2 Institute for Heart and Lung Health.|5 Department of Pathology and Laboratory Medicine, and.|4 PROOF Centre of Excellence, Vancouver, British Columbia, Canada.
authors.forename: Bruce M
authors.initials: BM
authors.lastname: McManus
authors.affiliation: 6 Department of Computer Sciences, University of British Columbia, Vancouver, British Columbia, Canada; and.|4 PROOF Centre of Excellence, Vancouver, British Columbia, Canada.
authors.forename: Raymond T
authors.initials: RT
authors.lastname: Ng
mesh_terms: D018450:Disease Progression; D020869:Gene Expression Profiling; D005819:Genetic Markers; D006801:Humans; D055432:Metabolomics / Q000379:methods; D057285:Precision Medicine / Q000379:methods*; D011379:Prognosis; D040901:Proteomics / Q000379:methods; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology; D018570:Risk Assessment / Q000379:methods
chemical_list: D005819:Genetic Markers
keywords: biomarkers; chronic obstructive pulmonary disease; personalized medicine